Delivery Order SPE2DB22D3501-SPE2DB25FVB68

Award Date 3/27/25
Potential Completion Date 3/28/25
Potential Value $3.4K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $14,293.56 Delivery Order contract is for the supply of RUXIENCE 500 MG/50 ML VIAL 50ML, a pharmaceutical product. This order is part of a larger Indefinite Delivery Contract (IDC) valued at $999,999,999 between AmerisourceBergen and the DLA Troop Support Medical, which serves as a primary vehicle for providing a...
This is a federal contract award from the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $3,155.70 delivery order is for the supply of RUXIENCE 500 MG/50 ML VIAL 50ML, a pharmaceutical product, with a completion date of April 15, 2025. The contract is a firm fixed-price delivery order, which is part of a larger Indefinite Delivery Contract (IDC) valued at $999,999,999 between AmerisourceBergen and the DLA...
This federal contract award, valued at $2,446.10, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of RUXIENCE 500 MG/50 ML VIAL 50ML, a pharmaceutical product, to support military healthcare programs. The contract has an ultimate completion date of January 21, 2025 and is a Firm Fixed Price Delivery Order, with no set-aside designation indicated....
This is a federal contract award from the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of RUXIENCE 500 MG/50 ML VIAL 50ML, a pharmaceutical product, with a ceiling value of $7,424.28. The contract is a Delivery Order under a larger Indefinite Delivery Contract (IDC) valued at $999,999,999 and running through November 2026, which serves as a primary vehicle for providing a...
This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $4,892.20 firm fixed-price delivery order is for the supply of RUXIENCE 500 MG/50 ML VIAL 50ML, a pharmaceutical product, with a period of performance through January 8, 2025. Amerisourcebergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical valued at $999,999,999 through...
This federal contract award, valued at $1,997.74, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major supplier of pharmaceutical products and medical supplies to the U.S. government. The contract is for the delivery of RUXIENCE 500 MG/50 ML VIAL 50ML, a pharmaceutical product, with a completion date of May 17, 2024. Amerisourcebergen holds a larger Indefinite Delivery Contract (IDC) worth up to $999,999,999.00 with the DLA Troop Support Medical, which...
This is a federal delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $13,847.91, is for the supply of RUXIENCE 500 MG/50 ML VIAL 50ML, a pharmaceutical product. The contract has an ultimate completion date of December 2, 2024 and is a Firm Fixed Price contract. This award is associated with a larger Indefinite Delivery Contract (IDC) that...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of RUXIENCE 500 MG/50 ML VIAL 50ML, a pharmaceutical product, to support federal medical supply requirements. The contract is a Firm Fixed Price Delivery Order with a ceiling value of $7,892.72 and a period of performance extending through May 14, 2025. It is not designated as a...
This is a federal contract award from the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $1,789.36, is for the delivery of Ruxience 500 mg/50 ml vial, a pharmaceutical product. The contract is a Firm Fixed Price Delivery Order with a completion date of February 26, 2025. The award is part of a larger Indefinite Delivery Contract (IDC) between AmerisourceBergen and the DLA Troop Support...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $4,892.20 firm-fixed-price delivery order is for the drug RUXIENCE 500 MG/50 ML VIAL 50ML, with a completion date of March 20, 2025. The award is part of a larger $999,999,999 Indefinite Delivery Contract (IDC) held by AmerisourceBergen with the DLA Troop Support Medical, which serves as a primary vehicle for...
  • SPE2DB22D3501
    Indefinite Delivery Contract
  • SPE2DB22D3501-SPE2DB25FVB68
    Delivery Order

This federal contract award, valued at $3,424.50, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of RUXIENCE 500 MG/50 ML VIAL 50ML, a pharmaceutical product, with a period of performance ending on March 28, 2025. The contract is a Delivery Order under a larger Indefinite Delivery Contract (IDC) held by AmerisourceBergen with the DLA Troop Support Medical, valued at $999,999,999 and running through November 2026. This IDC serves as a primary vehicle for providing a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally. The contract award does not have a set-aside designation, indicating open competition.

Generated 6/26/25, 10:12 AM